PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: MDxHealth, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

MDxHealth Presents SelectMDx™ Results from Multicenter Validation Study at the 2016 Annual EAU Congress - SelectMDx awarded best poster presentation by EAU's Scientific Congress Office - MDxHealth.com
MDxHealth Presents SelectMDx™ Results from Multicenter Validation Study at the 2016 Annual EAU Congress

 

NewswireToday - /newswire/ - Irvine, CA, United States, 2016/03/14 - SelectMDx awarded best poster presentation by EAU's Scientific Congress Office - MDxHealth.com. NYSE Euronext: MDXH

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

MDxHealth SA, announced today that positive results of a prospective, multicenter validation study of SelectMDx™ for Prostate Cancer were presented at the 2016 Annual European Association of Urology (EAU) Congress, March 11-15 in Munich, Germany.

The major challenge in prostate cancer (PCa) diagnostics is to improve the early detection of aggressive and potentially lethal prostate cancer. Ideally, prostate cancer-specific biomarkers could be assessed non-invasively, for example in urine. The aim of this study was to develop and validate a model that combines such biomarkers with traditional risk factors into a risk score that expresses an individual patient's risk of harboring high-grade prostate cancer.

Urine samples from two prospective, multicenter studies (cohort A: n=492 and cohort B: n=371) were collected after digital rectal examination (DRE) to measure the mRNA expression levels of the two genes included in the SelectMDx test. These results were combined with traditional clinical risk factors, i.e. DRE, PSA, PSA density, age and family history to further improve patient stratification. An algorithm was developed in cohort A, and successfully validated in the independent cohort B. The optimal model was generated to assess the likelihood of detecting high-grade disease upon biopsy for an individual patient. The SelectMDx urinary molecular biomarker-based risk score resulted in an improved detection of men harboring high-grade PCa, with a negative predictive value (NPV) for significant cancer of 98% and an area under the curve (AUC) of 0.88.

"This multicenter validation study demonstrates that the non-invasive SelectMDx test is able to effectively predict the presence of high-grade prostate cancer from urine samples collected from men with an increased PSA level," reported Dr. Jack Schalken, Professor of Experimental Urology at the Radboud Medical Center in Nijmegen, The Netherlands. "The very high NPV of the test could reduce unnecessary biopsies by approximately 50%, as well as other expensive diagnostic procedures such as MRI scans, and thus could result in significant cost savings for healthcare providers."

The poster presentation, entitled 'Multicenter validation study of a urine-based molecular biomarker algorithm to predict high-grade prostate cancer' (Abstract #383), was presented by Rianne Hendriks, MD at the 'Novel Biomarkers for Prostate Cancer Prediction' session (poster session 31) and was awarded a best poster presentation out of over 1100 submitted abstracts, by EAU's Scientific Congress Office. The full poster and abstract can be accessed via the EAU website (eaumunich2016.uroweb.org/).

About SelectMDx™ for Prostate Cancer
Of the nearly 2 million prostate biopsies performed each year, in less than 20% significant cancer is found. Most of these men could have avoided a painful and invasive prostate biopsy procedure, with its associated side effects and costs. SelectMDx for Prostate Cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive "liquid biopsy" method to identify patients at low risk for prostate cancer, helping to both reduce unnecessary prostate biopsy procedures with their concomitant complications and expense and to identify those men at increased risk of harbouring high-grade disease who may benefit most from earlier detection.

About MDxHealth
MDxHealth (mdxhealth.com) is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic and epigenetic (methylation) molecular technologies and assist physicians with the diagnosis of urological cancer, prognosis of recurrence risk, and prediction of response to a specific therapy.

Contacts: Amber Fennell, Chris Welsh, Hendrik Thys (PR & IR)
Consilium Strategic Communications
P: +44(0)20 3709 5701 / +1 917-322-2571 (Rx Communications Group LLC)
E: mdxhealth[.]consilium-comms.com.

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: MDxHealth, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


MDxHealth Presents SelectMDx™ Results from Multicenter Validation Study at the 2016 Annual EAU Congress

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

SelectMDx™ | EAU's Scientific Congress
Publisher Contact: Dr. Jan Groen - MDxHealth.com 
949-812-6979 / +32 4 364 20 70 info[.]mdxhealth.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any MDxHealth, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From MDxHealth, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Triggr & Bloom

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)